Biopharmaceutical company focusing on advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) announced that the World Intellectual Property Organization (WIPO) had published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules which the company had submitted an application for.
Cybin had submitted a Patent Cooperation Treaty (PCT) patent application on the above coverage under the patent application number PCT/EP2021/077057. This patent will strengthen the company’s long term intellectual property position in the psychedelic sector.
The PCT application is titled ‘Methods For Delivery Of Psychedelic Medications By Inhalation And Systems For Performing The Methods’ and it enables the company to go ahead with patent applications and seek protection from multiple inhaled forms of psychedelics molecules which Cybin is currently conducting research on or developing.
“The publication of this PCT patent application demonstrates our continued commitment to discovering and developing new psychedelic-based treatment options, in addition to identifying and combining potentially improved and well-controlled delivery systems with these clinical candidates. In addition, our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation, which is aimed at overcoming some of the known challenges of oral and IV-administered DMT,” said the CEO of Cybin, Doug Drysdale.